EPHA2 and melanoma: However, aberrant activation of EphA2 has been documented in cancer initiation and progression in several human malignancies, including breast [32,33], prostate [34], bladder [35], colorectal [36], nasopharyngeal [37], lung [38,39], glioblastoma [40], ovarian [41], gastric [42], and melanoma [43] tumors as well as bone sarcomas, including osteosarcoma, EWS, and chondrosarcoma [44,45].